Trials / Completed
CompletedNCT01094405
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy (clinical benefit rate) of MVA EBNA1/LMP2 vaccine in patients with persistent, recurrent or metastatic nasopharyngeal carcinoma, and its impact on disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Epstein-Barr Virus (EBV) Vaccine |
Timeline
- Start date
- 2010-03-31
- Primary completion
- 2020-08-27
- Completion
- 2020-08-27
- First posted
- 2010-03-29
- Last updated
- 2021-07-28
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT01094405. Inclusion in this directory is not an endorsement.